By Market Intelligence Team

OPEN MINDS The Behavioral Health & Social Service Industry Analyst Industry News The U.S. Food And Drug Administration (FDA) is soon expected to approve Imigran, a drug developed by Glaxo Holdings PLC for the treatment of migraine headaches. Imigran is one of two drugs to be introduced by Glaxo (the other being ondansetron for chemotherapy) based on serotonin research. The first such drug introduced was Eli Lilly & Company’s Prozac, according to a report by Michale Waldholz, "Brain Explorers Use Chemical Messengers To Design New Drug," that appeared in . . .
Restricted Content

You must be a member to view this resource.

Log in | Sign up or learn more about membership options
OPEN MINDS The Behavioral Health & Social Service Industry Analyst Industry News The U.S. Food And Drug Administration (FDA) is soon expected to approve Imigran, a drug developed by Glaxo Holdings PLC for the treatment of migraine headaches. Imigran is one of two drugs to be introduced by Glaxo (the other being ondansetron for chemotherapy) based on serotonin research. The first such drug introduced was Eli Lilly & Company’s Prozac, according to a report by Michale Waldholz, "Brain Explorers Use Chemical Messengers To Design New Drug," that appeared in . . .
Restricted Content

You must be a member to view this resource.

Log in | Sign up or learn more about membership options

Login to access The OPEN MINDS Circle Library. Not a member? Create your free account now!